TrialSignal transduction and targeted therapy2023

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.

Javier Martin-Broto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.